Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People whose lymphoma has come back after treatment, or whose disease did not respond well enough to at least 2 previous treatment plans.
• People who have been confirmed through a tissue test (biopsy) to have either follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL).
• For people with DLBCL only: the disease has continued to grow after a stem cell transplant, or the treating doctor has determined they are not suitable for a transplant or a specialised cell therapy called CAR-T therapy.
• People who are able to provide a tumour tissue sample, either from a previously stored sample or a newly collected one (if done as part of standard care).
• People whose tumour tissue, tested after a previous treatment that targeted a protein called CD19, still shows signs of that protein — this applies only if their disease progressed after such a treatment.
• People living with HIV whose infection is well-managed with medication.
• People who have hepatitis B, provided the virus is undetectable in their blood and they are receiving and will continue to receive antiviral treatment.
• People who have had hepatitis C, provided the virus is no longer detectable in their blood following antiviral treatment.
• People whose disease can be measured on a scan, according to a standard measurement system called the Lugano Response Criteria.

Who may not be able to join:

• People who have previously received a solid organ transplant (such as a kidney, liver, or heart).
• People who have had or currently have significant diseases affecting the brain or spinal cord.
• People with a history of serious heart or stroke-related conditions.
• People who have had an allogeneic stem cell transplant (a transplant using a donor's cells) and experienced a serious immune reaction called acute graft-versus-host disease (GVHD), or who currently show signs of ongoing GVHD, or who still need medication to suppress their immune system because of GVHD.
• People living with HIV who have also had a condition called Kaposi's sarcoma or Multicentric Castleman's Disease.
• People who have received a live vaccine within 30 days before joining the trial.
• People who have received CAR-T therapy within 3 months before the first dose of the trial treatment.
• People who have another cancer that is still growing or required active treatment within the past 2 years.
• People whose lymphoma has spread to or is active in the brain or spinal cord.
• People who have an autoimmune disease (where the immune system attacks the body) that required treatment with medication in the past 2 years.
• People who currently have an active infection that requires medication.
• People with a history of severe bleeding disorders.
• People who have not yet recovered from major surgery, or who have ongoing complications from surgery.
• People diagnosed with a specific type of lymphoma called primary mediastinal B-cell lymphoma.

Important: Always verify eligibility with the trial site directly before applying.